PRB develops patent protectable new drugs and treatment concepts based on exisiting compounds (drugs or endogenous molecules) up to proof-of-concept (phase II) in the human. PRB is specialised in the area of Women's Health including hormonal contraception, hormone replacement therapy (HRT), infertility, osteoporosis, osteoarthritis and cancer of reproductive organs such as the breast, the ovary and the prostate.
PRB has currently prioritised the following projects:

1. Estetrol (E4 project): a fetal estrogen, suitable for oral contraception, bone disease, and HRT, including HRT in women with breast cancer.

2. Androgen Restored Contraception (ARC project): restoration of testosterone levels in women using oral contraception

3. Zona Pellucida (ZP project): active immunization with zona pellucida antigens for the treatment of ovarian cancer